BR112016028875A2 - formulações intravaginais compreendendo gnrh - Google Patents

formulações intravaginais compreendendo gnrh

Info

Publication number
BR112016028875A2
BR112016028875A2 BR112016028875A BR112016028875A BR112016028875A2 BR 112016028875 A2 BR112016028875 A2 BR 112016028875A2 BR 112016028875 A BR112016028875 A BR 112016028875A BR 112016028875 A BR112016028875 A BR 112016028875A BR 112016028875 A2 BR112016028875 A2 BR 112016028875A2
Authority
BR
Brazil
Prior art keywords
gnrh
formulation
amount
intravaginal
offered
Prior art date
Application number
BR112016028875A
Other languages
English (en)
Inventor
P Kolbasa Karen
L Feenstra Kenneth
Luo Laibin
A Wicks Nicholas
C Sucheta Susan
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of BR112016028875A2 publication Critical patent/BR112016028875A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

é oferecida uma formulação intravaginal, compreendendo um ácido carboxílico em uma quantidade de 10-20% p/p da referida formulação, uma base oleaginosa, tendo uma temperatura de fusão entre 30¿c e 38¿c, gnrh ou um análogo do mesmo, em uma quantidade equivalente à quantidade de gnrh entre 10 µg e 600 µg. também é oferecido um para induzir a ovulação em um ruminante usando a formulação.
BR112016028875A 2014-06-16 2015-06-03 formulações intravaginais compreendendo gnrh BR112016028875A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462012523P 2014-06-16 2014-06-16
PCT/US2015/033951 WO2015195333A1 (en) 2014-06-16 2015-06-03 Intravaginal formulations comprising gnrh

Publications (1)

Publication Number Publication Date
BR112016028875A2 true BR112016028875A2 (pt) 2017-08-22

Family

ID=53773489

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016028875A BR112016028875A2 (pt) 2014-06-16 2015-06-03 formulações intravaginais compreendendo gnrh

Country Status (14)

Country Link
US (1) US20170143786A1 (pt)
EP (1) EP3154519A1 (pt)
JP (1) JP2017519769A (pt)
CN (1) CN106456705A (pt)
AR (1) AR100846A1 (pt)
AU (1) AU2015277613A1 (pt)
BR (1) BR112016028875A2 (pt)
CA (1) CA2951532A1 (pt)
CL (1) CL2016003220A1 (pt)
IL (1) IL249121A0 (pt)
MX (1) MX2016016768A (pt)
RU (1) RU2016146994A (pt)
UY (1) UY36168A (pt)
WO (1) WO2015195333A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11376220B2 (en) 2017-06-30 2022-07-05 Therio, LLC Single-injection methods and formulations to induce and control multiple ovarian follicles in bovine, caprine, ovine, camelid and other female animals

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211769A (en) * 1977-08-24 1980-07-08 Takeda Chemical Industries, Ltd. Preparations for vaginal administration
AU2063197A (en) * 1996-03-04 1997-09-22 Massachusetts Institute Of Technology Materials and methods for enhancing cellular internalization
CN101692985A (zh) * 2009-09-29 2010-04-14 浙江大学 一种诱导奶牛定时***进行人工授精的方法
CN101779988A (zh) * 2010-02-03 2010-07-21 李树静 一种青年牛高强度重复超数***的方法

Also Published As

Publication number Publication date
MX2016016768A (es) 2017-04-04
CA2951532A1 (en) 2015-12-23
US20170143786A1 (en) 2017-05-25
CL2016003220A1 (es) 2017-06-02
RU2016146994A (ru) 2018-07-16
JP2017519769A (ja) 2017-07-20
RU2016146994A3 (pt) 2018-07-16
IL249121A0 (en) 2017-01-31
AU2015277613A1 (en) 2016-12-08
UY36168A (es) 2016-01-29
AR100846A1 (es) 2016-11-02
CN106456705A (zh) 2017-02-22
EP3154519A1 (en) 2017-04-19
WO2015195333A1 (en) 2015-12-23

Similar Documents

Publication Publication Date Title
CL2021000343A1 (es) Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)
CL2018000320A1 (es) Coadyuvantes basados en aceite (divisional de solicitud 201600650)
CO2017005626A2 (es) Una composición que comprende bacteroides thetaiotaomicron
IL255203B (en) Topical pharmaceutical emulsion compositions comprising 3,5-dihydroxy-4-isopropyl-trans-stilbene and use thereof in the treatment or prophylaxis of dermatological conditions or disorders
NI201700073A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
BR102016017090B8 (pt) Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
WO2015160842A8 (en) Methods and formulations of capsaicinoids and capsinoids
BR112015023391A2 (pt) formulações compreendendo conjugado droga-anticorpo anti-egfr
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
BR112017012562A2 (pt) lubrificante para alta temperatura para a indústria alimentícia
BR112015019264A2 (pt) composições farmacêuticas para o tratamento de helicobacter pylori
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
CO2019002245A2 (es) Combinación de agonistas de fxr
BR112017028137A2 (pt) agente terapêutico para fibrose
AR112291A1 (es) Composición para su uso en la prevención y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncológico
BR112018074006A2 (pt) extrato de farelo de trigo em uma mistura para cuidado capilar
BR112016028875A2 (pt) formulações intravaginais compreendendo gnrh
AR108616A1 (es) Formulación combinada de tres compuestos antivirales
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
BR112017025043A2 (pt) formulação para cuidado dos cabelos
MX2017013879A (es) Composiciones que comprenden anakinra.
IL271596B2 (en) An emulsion preparation that includes danzol for use in the treatment of bread mucosa conditions
BR112017017308A2 (pt) composição de graxa
BR112017017685A2 (pt) formulações farmacêuticas de inibidor de c1 esterase

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements